Full text is available at the source.
Abstract
Dual and triple incretin-based therapies are transforming treatment for type 2 diabetes, obesity, and non-alcoholic fatty liver disease.
- These therapies target multiple receptors, including those for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
- They may enhance glycemic control and contribute to weight reduction.
- Drugs such as tirzepatide and retatrutide have demonstrated unprecedented efficacy and tolerability.
- The mechanisms and clinical progress of these agents suggest potential benefits beyond current GLP-1-based therapies.
- Challenges related to safety, accessibility, and long-term use remain.
Simplified